ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension | Circulation Science
Volunteer Warning signs SearchSearch Advanced Search Donate Circulation logo Hello Guest …

elevated in patients with PAH, 13 and clearance of endothelin in the pulmonary vasculature
is reduced. 14 Endothelin acts at 2 different receptors: ETA receptors on vascular smooth …

A consensus panel convened by the American College of Chest Physicians developed
guidelines for the treatment of pulmonary arterial hypertension (PAH) that were published in …

Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol
improves exercise capacity and haemodynamics in PAH, and increases survival in …

Addition of inhaled iloprost to bosentan may have beneficial effects in patients with
idiopathic pulmonary arterial hypertension (IPAH). A multicentre, open, randomised …

Prostacyclin and its analogues (prostanoids) are potent vasodilators and possess
antithrombotic, antiproliferative and anti-inflammatory properties. Pulmonary hypertension …

The characteristics of pulmonary arterial hypertension (PAH), including pathology,
symptoms, diagnosis and treatment are reviewed in children and adults. The histopathology …

The numerous controlled clinical trials performed recently in pulmonary arterial hypertension
(PAH) can allow us to abandon a clinical-based treatment strategy and adopt an evidence …

Raynaud's phenomenon is a common clinical disorder for which patients frequently seek the
expertise and care of dermatologists. It is manifested by recurrent vasospasm of the fingers …

2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic
pulmonary hypertension | Avdeev | Russian Journal of Cardiology Russian Journal of …